A icon

Agilent Technologies

100.26 USD
-2.22
2.17%
At close Apr 21, 4:00 PM EDT
After hours
100.26
+0.00
0.00%
1 day
-2.17%
5 days
-4.46%
1 month
-16.97%
3 months
-34.29%
6 months
-26.69%
Year to date
-24.86%
1 year
-25.13%
5 years
35.95%
10 years
133.76%
 

About: Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Employees: 17,900

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

50% more call options, than puts

Call options by funds: $164M | Put options by funds: $109M

49% more first-time investments, than exits

New positions opened: 134 | Existing positions closed: 90

2% more funds holding

Funds holding: 1,034 [Q3] → 1,058 (+24) [Q4]

2.09% more ownership

Funds ownership: 86.18% [Q3] → 88.27% (+2.09%) [Q4]

4% less repeat investments, than reductions

Existing positions increased: 363 | Existing positions reduced: 377

8% less capital invested

Capital invested by funds: $36.6B [Q3] → $33.9B (-$2.79B) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 12 [Q3] → 8 (-4) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$115
15%
upside
Avg. target
$136
36%
upside
High target
$159
59%
upside

5 analyst ratings

positive
40%
neutral
60%
negative
0%
Jefferies
Brandon Couillard
24% 1-year accuracy
6 / 25 met price target
16%upside
$116
Hold
Maintained
21 Apr 2025
Wells Fargo
Brandon Couillard
24% 1-year accuracy
6 / 25 met price target
35%upside
$135
Overweight
Maintained
17 Apr 2025
Barclays
Luke Sergott
28% 1-year accuracy
16 / 57 met price target
15%upside
$115
Equal-Weight
Maintained
10 Apr 2025
Baird
Catherine Schulte
0% 1-year accuracy
0 / 20 met price target
59%upside
$159
Outperform
Maintained
27 Feb 2025
B of A Securities
Derik De Bruin
35% 1-year accuracy
7 / 20 met price target
56%upside
$156
Neutral
Maintained
27 Jan 2025

Financial journalist opinion

Based on 4 articles about A published over the past 30 days

Neutral
Business Wire
4 days ago
Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced.
Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Positive
Zacks Investment Research
1 week ago
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Positive
Seeking Alpha
2 weeks ago
Fear Creates Fortunes: Grab These 7 Blue-Chip Bargains Today
Fear at extremes: Investor and consumer sentiment is near historic lows, signaling a high-probability buying opportunity, historically followed by strong 12-month gains. Economic reality check: Real-time economic indicators show GDP growth of more than 2%, despite widespread recession fears, highlighting a disconnect between sentiment and fundamentals. Inflation truth vs. hype: Real-time data shows inflation is falling, contradicting consumer fears and demonstrating that stagflation panic may be premature.
Fear Creates Fortunes: Grab These 7 Blue-Chip Bargains Today
Neutral
Business Wire
4 weeks ago
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a.
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval
Neutral
Business Wire
1 month ago
CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025
SANTA CLARA, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will.
CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025
Neutral
Business Wire
1 month ago
Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzing tissue samples, often for dia.
Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025
Neutral
Business Wire
1 month ago
Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Columbia University has received an Agilent Research Catalyst (ARC) Award on behalf of Dr. Pawel Muranski, an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Med.
Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski
Neutral
Business Wire
1 month ago
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusiv.
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Neutral
Seeking Alpha
1 month ago
Agilent Technologies, Inc. (A) TD Cowen 45th Annual Healthcare Conference (Transcript)
Agilent Technologies, Inc. (NYSE:A ) TD Cowen 45th Annual Healthcare Conference Call March 4, 2025 9:50 AM ET Company Participants Padraig McDonnell - Chief Executive Officer Bob McMahon - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Daniel Brennan Alright, good. I guess we'll start in a minute or two early here, great day two of the TD Cowen Global Healthcare Conference.
Agilent Technologies, Inc. (A) TD Cowen 45th Annual Healthcare Conference (Transcript)
Neutral
Zacks Investment Research
1 month ago
Unlocking Agilent (A) International Revenues: Trends, Surprises, and Prospects
Explore how Agilent's (A) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Unlocking Agilent (A) International Revenues: Trends, Surprises, and Prospects
Charts implemented using Lightweight Charts™